The preliminary filing lacks pricing and share count, so the immediate impact is limited to the dilutive signal of a new equity offering. Monitor for the final priced prospectus supplement to assess the actual offering size and discount to market. The $451.6M remaining ATM capacity adds overhang risk.
Price Chart
Executive Summary
Spyre Therapeutics filed a preliminary 424B5 prospectus supplement for an underwritten common stock offering of an undisclosed number of shares, with an option for underwriters to purchase additional shares. The offering is being conducted under the existing S-3ASR shelf filed June 26, 2026. The filing contains no pricing or share count — all dollar and share fields are placeholder values — making this a preliminary filing with no actionable financial terms.
Key Facts
- Preliminary prospectus supplement filed October 5, 2026 for an underwritten common stock offering; all pricing and share count fields are blank placeholders.
- Last reported sale price on October 2, 2026 was $93.19 per share.
- Underwriters include Jefferies, TD Cowen, Leerink Partners, Stifel, and LifeSci Capital (passive bookrunner).
- Underwriters granted a 30-day option to purchase additional shares at the public offering price less underwriting discounts.
- Pro forma net tangible book value per share as of June 30, 2026 was $10.81 (assuming preferred stock conversion).
- Cash balance as of June 30, 2026 was approximately $1.1 billion, expected to fund operations into second half of 2029.
- Proceeds intended to fund pipeline programs in gastroenterology, rheumatology, and dermatology, including SPY072 late-stage development for HS.
- Approximately $451.6 million remains available for sale under the existing ATM Sales Agreement with TD Securities.
- Lock-up agreements with company, executive officers, and directors restrict sales for 60 days after the offering date.
Financial Impact
Undisclosed — all offering size and pricing fields are placeholder values. The company had ~$1.1B cash as of June 30, 2026 and a $7.8B market cap at the time of the S-3ASR filing.
Risk Factors
- Immediate and substantial dilution to existing shareholders once pricing is set.
- Potential for further dilution from the underwriters' option and remaining ATM capacity.
- Stock price may decline upon final pricing if the discount to market is significant.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001628280-26-064924 |
| Document: 0001628280-26-064924-index-headers.html | 0001628280-26-064924 |
| Document: 0001628280-26-064924-index.html | 0001628280-26-064924 |
| Document: 0001628280-26-064924.txt | 0001628280-26-064924 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 15d ago | Institutional Cluster | $85.90 | awaiting T+20 | — | $99.04 (+15.30%) |
Oct 9, 2026 18d ago | SC 13D/A | $85.90 | awaiting T+20 | — | $99.04 (+15.30%) |
Oct 7, 2026 20d ago | 8-K | $80.85 | awaiting T+20 | — | $99.04 (−22.50%) |
Oct 6, 2026 21d ago | 424B5 | $80.85 | awaiting T+20 | — | $99.04 (−22.50%) |
Oct 5, 2026 22d ago | Press Release | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 5, 2026 22d ago | 424B5 | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 5, 2026 22d ago | Press Release | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 2, 2026 25d ago | Insider Cluster | $92.72 | awaiting T+20 | — | $99.04 (−6.82%) |
Sep 3, 2026 7w ago | Insider Cluster | $88.98 $92.72 | ▼ −4.20% | ▼ −3.60% | $99.04 (−11.31%) |
Aug 10, 2026 11w ago | Insider Cluster | $102.74 $86.93 | ▲ +15.39% | ▲ +14.33% | $99.04 (+3.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers